Trial Profile
A Non-Randomized, Open Label, Controlled, Dose-Escalation, Phase I Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of One or Two Administrations of Candidate Rabies mRNA Vaccine CV7202 in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2022
Price :
$35
*
At a glance
- Drugs CV-7202 (Primary) ; Rabies vaccine
- Indications Rabies
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors CureVac
- 22 Dec 2021 Status changed from active, no longer recruiting to completed.
- 12 Jan 2021 Results published in the Vaccine
- 13 Mar 2020 Planned End Date changed from 1 Jan 2021 to 1 Jan 2023.